Pancreatic Cancer
-
New Horizons in Pancreatic Oncology: Can-Fite Moves to Phase 2b as Mitochondrial ‘Addiction’ Discovery Unveils Fatal Vulnerability
Significant clinical and biological breakthroughs are reshaping the landscape of pancreatic adenocarcinoma treatment, led by Can-Fite’s advancement of Namodenoson to Phase 2b and the discovery of a mitochondrial inflammatory pathway that fuels tumor growth.
-
New Pancreatic Cancer Breakthrough Offers Unprecedented Survival
A new oral drug, daraxonrasib, has demonstrated unprecedented survival benefits in Phase 3 trials for pancreatic cancer, offering a potential shift in treatment standards.
-
Ben Sasse Spotlights Experimental Pancreatic Cancer Drug
Former Senator Ben Sasse’s public treatment with the experimental drug daraxonrasib has intensified focus on potential breakthroughs for late-stage pancreatic cancer.
-
Pancreatic Cancer Eradicated in Mice: Why Human Trials Remain Distant
A new triple-combination drug therapy developed by Spanish scientists has completely and permanently eliminated pancreatic tumors in mice, addressing a major challenge of treatment resistance. However, human clinical trials are still a long way off.
-
Mariano Barbacid’s Team Unveils Triple Therapy Breakthrough for Pancreatic Cancer
A research team led by Dr. Mariano Barbacid at Spain’s National Center for Oncological Research (CNIO) has reported a significant breakthrough in treating pancreatic cancer. Their novel triple-drug therapy completely eliminated aggressive tumors in mouse models, offering new hope against…
-
Ben Sasse Faces Terminal Pancreatic Cancer: Legacy, Faith, and Public Response
Former U.S. Senator and University of Florida president Ben Sasse has announced his diagnosis of terminal stage-four pancreatic cancer, prompting reflections on his public service, personal resilience, and the responses from leaders nationwide.